Tardive Dyskinesia News and Research

RSS
Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may appear as though the patient is playing an invisible guitar or piano.
U.S. Supreme Court ruling on generic drugs

U.S. Supreme Court ruling on generic drugs

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Latest achievements in brain research and treatment for mental disorders

Latest achievements in brain research and treatment for mental disorders

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Despite FDA black box warning, prescription of Reglan for premature infants continue

Despite FDA black box warning, prescription of Reglan for premature infants continue

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves once-daily SEROQUEL XR Extended Release Tablets

FDA approves once-daily SEROQUEL XR Extended Release Tablets

FDA approves sNDA for pediatric autism drug ABILIFY

FDA approves sNDA for pediatric autism drug ABILIFY